Low-Dose Ponatinib in Intolerant Chronic Myeloid Leukemia Patients: A Safe and Effective Option

Clin Drug Investig. 2018 May;38(5):475-476. doi: 10.1007/s40261-018-0623-7.

Authors

Alessandra Iurlo¹, Daniele Cattaneo², Nicola Orofino², Cristina Bucelli², Matteo Molica³, Massimo Breccia³

Affiliations

¹ Hematology Division, IRCCS Ca' Granda-Maggiore Policlinico Hospital Foundation, University of Milan, Via Francesco Sforza 35, 20122, Milan, Italy. alessandra.iurlo@policlinico.mi.it.
² Hematology Division, IRCCS Ca' Granda-Maggiore Policlinico Hospital Foundation, University of Milan, Via Francesco Sforza 35, 20122, Milan, Italy.
³ Department of Cellular Biotechnologies and Hematology, University "La Sapienza" of Rome, Rome, Italy.

PMID: 29363026
DOI: 10.1007/s40261-018-0623-7

No abstract available

Publication types

Letter